The FDA has already approved Yescarta in DLBCL for the US market, while the European Medicines Agency is reviewing Gilead’s filing and is due to make a decision in the first half of this year.

Yescarta (axicabtagene ciloleucel) has been approved as a treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma ...

followed by Stage I in 2023 in the US. .Approved drugs for the treatment of Diffuse Large B-Cell Lymphoma include RITUXAN/MABTHERA (rituximab), YESCARTA (axicabtagene ciloleucel), KYMRIAH ...

Dr. Sattva S. Neelapu discusses how the CAR-T therapy Yescarta impacts the quality of life of patients with R/R indolent non-Hodgkin lymphoma. Dr. Sattva S. Neelapu, a professor and deputy department ...

"As a result of my DLBCL, I have to cope with constant fatigue, fear of relapse and the harsh side effects of existing treatments. The approval of Yescarta means more patients in Scotland can be ...

"As a result of my DLBCL, I have to cope with constant fatigue, fear of relapse and the harsh side effects of existing treatments. The approval of Yescarta means more patients in Scotland can be ...

In Canada, 1 in 12 people live with a rare disease, and for most people affected, the cost of treatment is unaffordable. Canadians deserve a health care system that provides timely access to quality ...

Yescarta demonstrates a five-year median duration of response, surpassing traditional therapies for relapsed/refractory follicular lymphoma. CAR-T cell therapy is potentially curative, with a plateau ...

– Largest Real-World Evidence (RWE) Analysis of Yescarta in Second-Line Shows 71% Overall Survival Rate, Consistent with Pivotal ZUMA-7 Study, in Broader Patient Population with Relapsed ...

Health CanadaIn Canada, 1 in 12 people live with a rare disease, and for most people affected, the cost of treatment ...